Altogether, these findings support the notion that HER2-low breast cancer should not be considered a distinct molecular entity, but rather a group of heterogenous tumors with either luminal-like features or TNBC-like characteristics, modulated by HR expression. Here, ERBB2 is linked to breast carcinoma.